Author

E. Stepanova

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

F. Loayza-Puch· 2 shared A. Hedley· 1 shared C. Boldrini· 1 shared C. F. Calkhoven· 1 shared C. Jamieson· 1 shared C. Miller· 1 shared C. Müller· 1 shared C. Riero Domingo· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

F. Loayza-Puch

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Oncogenic functions of the m6A demethylase FTO in breast cancer cells involving translational upregulation of C/EBPβ-LIP

H. R. Zuidhof, C. Müller, G. Kortman, R. Wardenaar, E. Stepanova, F. Loayza-Puch, C. F. Calkhoven

This study shows FTO promotes oncogenic functions in TNBC by regulating C/EBPβ-LIP translation, which drives EMT and metastasis.

bioRxiv · Sep 21, 2023 · PreprintCancer Biology

PYCR1-dependent proline synthesis in cancer-associated fibroblasts is required for the deposition of pro-tumorigenic extracellular matrix

E. J. Kay, K. Paterson, C. Riero Domingo, D. Sumpton, H. Daebritz, S. Tardito, C. Boldrini, J. R. Hernandez-Fernaud, D. Athineos, S. Dhayade, E. Stepanova, E. Gjerga, L. J. Neilson, S. Lilla, A. Hedley, , S. Zanivan

This study identifies PYCR1-dependent proline synthesis in cancer-associated fibroblasts as critical for collagen production and tumor progression, suggesting PYCR1 as a therapeutic target to inhibit pro-tumorigenic extracellular matrix deposition.

bioRxiv · May 30, 2020 · PreprintCancer Biology